LYKA LABS LTD. - 500259 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 21St May 2024
LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 ,inter alia, to consider and approve The Company has informed that the meeting of Board of Directors of the Company is scheduled on 21st May 2024 to consider and approve standalone and consolidated financial results for the year ended 31st March 2024. LYKA LABS LTD. - 500259 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyLYKA LABS LTD. 2CIN NO.L24230GJ1976PLC008738 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 44.23 4Highest Credit Rating during the previous FY BBB+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Kishore P Shah Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Yogesh Shah Designation: Executive Director and CFO EmailId: [email protected] Date: 26/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. LYKA LABS LTD. - 500259 - Update On The Scheme Of Amalgamation
Update on the Scheme of Amalgamation w.r.t its next hearing is enclosed herewith. LYKA LABS LTD. - 500259 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
Certificate under Regulation 7 (3) of the SEBI ( Listing Regulations and Disclosure Requirements) Regulation, 2015 is enclosed. LYKA LABS LTD. - 500259 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ipca Laboratories Ltd & PACs LYKA LABS LTD. - 500259 - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
Certificate under regulation 40 (9) of the SEBI LODR Regulations 2015 is submitted herewith. LYKA LABS LTD. - 500259 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting LYKA LABS LTD. - 500259 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 16Th April 2024.
LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/04/2024 ,inter alia, to consider and approve to allot and issue 2600000 equity shares upon conversion of 2600000 warrants to Ipca Laboratories Limited. LYKA LABS LTD. - 500259 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Reg 74 (5) of the SEBI (DP) Regulations 2018, the Company enclosed herewith a certificate for the quarter ended 31st March 2024, as received from Registrar and Share Transfer Agent of the Company. LYKA LABS LTD. - 500259 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
The Company has issue duplicate share certificates on 5th April 2024.